Research area
Health & Longevity
Human health, disease, treatment and aging. The largest corpus area supports distinct cancer, neurological and therapeutic navigation.
-
Evidence date ·How did the five-part regimen affect resistant mouse tumors?
Peer-Reviewed PaperIn a mouse colon-tumor study, 67% of mice given a five-part immune regimen had tumors below 300 mm³, compared with at most 22% given shorter combinations.
-
Evidence date ·How could a dendritic-cell vaccine and nivolumab work together?
Review or Meta-AnalysisA 2021 review describes how dendritic-cell vaccines aim to rally cancer-fighting cells while nivolumab blocks a checkpoint that can blunt their attack.
-
Evidence date ·Why has one immune treatment helped while others face barriers in neuroblastoma?
Review or Meta-AnalysisDinutuximab improved outcomes in neuroblastoma, but a review finds few T and NK cells inside high-risk tumours and explores why broader immune therapies struggle.
-
Evidence date ·How can a possible immune side effect reach the oncology team?
Review or Meta-AnalysisTracked over timeAcross seven studies, some programs improved recognition of possible immune side effects; calls and electronic reports gave patients ways to alert care teams.
-
Evidence date ·How patients and carers helped shape five immunotherapy videos
Peer-Reviewed PaperTracked over timePatients and family carers helped shape five short videos about starting cancer immunotherapy, from infusion preparation to side effects and support.
-
Evidence date ·Why two people in their 70s may need different lymphoma treatment
Review or Meta-AnalysisA 2021 review shows how daily function and lymphoma biology inform chemotherapy choices; evidence comparing gentler regimens remains limited.
-
Evidence date ·How did survival differ by weight during immunotherapy for head and neck cancer?
Review or Meta-AnalysisTracked over timeIn six studies of head and neck cancer immunotherapy, underweight patients had poorer survival on two measures; obesity was linked to better overall survival only.
-
Evidence date ·How did body mass index relate to survival across kidney cancer treatments?
Review or Meta-AnalysisTracked over timeA 2024 review linked higher body mass index to longer survival with immunotherapy plus targeted drugs; immunotherapy-only studies showed no clear survival link.
-
Evidence date ·What can body mass index tell us about immunotherapy outcomes?
Review or Meta-AnalysisTracked over timeA review of 20 studies linked higher body mass index to longer survival and more immune-related side effects during immunotherapy; results varied by cancer and sex.
-
Evidence date ·What lignin, xylan and cellulose bring to drug carriers
Review or Meta-AnalysisA 2021 review describes far greater drug release from one xylan carrier with rat cecal and colonic contents, and compares lignin and cellulose carriers.